News Sentiment

KLRS sentiment intelligence

Kalaris Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.44 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.5% over one week, +2.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend inactive 2.5% over four weeks
Fair value -73.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 7
TradingView 6
TradingKey 4
The Manila Times 3
simplywall.st 3
dars.gov.et 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 18
Analyst action 5
Deals and strategy 3
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Stock Titan Direct company coverage

[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity

Kalaris Therapeutics, Inc. director Michael Dybbs was granted 9,000 stock options, with an exercise price of $4.72 per share and an expiration date of June 2, 2036. These options are scheduled to vest fully by June 3, 2027, or the date of the company's 2027 Annual Meeting of Stoc

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 20:08
Source
Stock Titan
Stock Titan Direct company coverage

Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares

Kalaris Therapeutics director David Hallal was granted stock options for 9,000 shares of common stock with an exercise price of $4.72 per share. The options, granted on June 3, 2026, vest in full on the earlier of June 3, 2027, or the company's 2027 annual stockholder meeting, co

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 20:08
Source
Stock Titan
ACCESS Newswire Direct company coverage

Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The Firm - KLRS

Kaskela Law LLC has initiated an investigation into potential legal claims for shareholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS). This follows a significant decline in Kalaris' stock price, dropping nearly 45% to under $5.00 per share since its merger with AlloVir, Inc. in

Tone
Negative 29/100
Event
Deals and strategy
Published
04 Jun 2026 07:59
Source
ACCESS Newswire